Chugai's Value Creation & Sustainability - Chugai reorganized its value creation process in 2024, using materiality as axes, aiming to realize advanced and sustainable patient-centric healthcare[9] - The company focuses on creating innovative drugs and services, providing individualized solutions, ensuring quality, and co-creating a healthcare ecosystem[12] - Chugai is implementing materiality by aligning business activities with its materiality story, reflected in management strategies and division activities[14, 16, 20] - A project using the antibody drug discovery support technology MALEXA has advanced to clinical development stage[22, 23] - The company is constructing a disease database for blood coagulation disorders in cooperation with patient associations and academia[29, 35] - Chugai achieved 100% renewable energy ratio in purchased electricity[39] Mid-Size Molecule Drug Platform - Chugai is establishing a pharmaceutical technology platform for mid-size molecule drugs to provide new treatment options[6, 52] - The company is developing a new liquid-phase synthesis method to improve the efficiency of producing mid-size molecules[65] - Through joint research, the cost of certain non-natural amino acids was reduced to less than one third[77] - A 55.5 billion yen investment was made in Fujieda in 2024, 128.8 billion yen in Yokohama in 2022, and 4.5 billion yen in Ukima in 2020[90] Governance and Shareholder Value - Chugai emphasizes dialogue with investors to enhance governance and increase shareholder value[120] - Non-executive directors play a key role in monitoring and advising on management from a global perspective[129] - The company's average annual Total Shareholder Return (TSR) for the past 10 years is 23.5%, compared to 9.5% for TOPIX and 7.8% for TOPIX-17 Pharmaceutical Index[150]

Immutep Overview - Immutep has approximately A$109.85 million in cash and cash equivalents, providing a runway to the end of CY2026[14] - Immutep is developing four clinical-stage assets, including eftilagimod alfa (efti) and IMP761, designed to empower the immune system to fight cancer and autoimmune diseases[14] TACTI-004 (KEYNOTE-F91) Phase III Trial - The NSCLC drug market is expected to reach US$48 billion in sales in 2031[14,24] - The TACTI-004 Phase III trial has activated over 100 clinical sites across 24 countries and enrolled over 170 patients as of October 2025[25,30] - MSD is supplying KEYTRUDA for the TACTI-004 trial, with a typical ICI supply value of approximately US$100 million[30,32] Efficacy and Safety - In the INSIGHT-003 trial, a 62.7% objective response rate and a 90.2% disease control rate were observed across all PD-L1 expression levels in first-line NSCLC patients[52] - The EFTISARC-NEO trial in soft tissue sarcoma met its primary endpoint, demonstrating a median 51.5% tumor hyalinization/fibrosis rate (p<0.001) with neoadjuvant efti + KEYTRUDA + radiotherapy[52,70] Financials - Immutep's total revenue and other income were A$10.3 million in FY25, compared to A$7.8 million in FY24[79,80] - Research and development and intellectual property expenses increased to A$61.4 million in FY25[79,80] - The company reported a net loss of A$61.4 million in FY25[79] Intellectual Property - In FY24, seven patents were granted for efti, including six patents for efti in combination with a PD-1 pathway inhibitor[84] - Seven patents were granted for IMP761 in FY24[84] Anti-PD-(L)1 Therapies Sales - KEYTRUDA sales were approximately $29.5 billion in 2024[50,51] - OPDIVO sales were approximately $9.3 billion in 2024[50,51]

Daikin's Growth in the North American Data Center Cooling Market November 27, 2025 Today's Agenda 2 • Data Center Market in North America and Our Strategic Goals • Evolving Cooling Needs and Our Initiatives • Future Outlook North American Data Center Cooling Market Trends and Our Perspective 0 0.5 1 1.5 2 2.5 3 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 North American Data Center Cooling market Trend (company estimate) (T JPY) Approx. ¥1.1T Approx. ¥2.7T 3 Our Business Plan and Strategy 2023 2025 203 ...

Company Overview - NOVONIX is positioned as a leading domestic supplier of battery-grade synthetic graphite in North America[32] - The company is commercializing patented cathode synthesis technology to minimize environmental impact while producing high-performance materials[32] - NOVONIX offers industry-leading Ultra-High Precision Coulometry cell testing equipment and R&D services[32] Market and Competition - China dominates graphite production and export, accounting for approximately 95% of global supply[42] - China has imposed and tightened export controls on certain graphite items[42] - The US faces a structural market deficit for traditional Active Anode Material (AAM), forecasted to exceed 500kt/year over the next decade[51] Industrialization and Production - NOVONIX's Riverside facility is scaling to 20k tpa aligned with customer demand[63] - The company was awarded a $100 million DoE MESC grant and allocated up to $103 million in 48C investment tax credit for the Riverside facility[63] - NOVONIX Enterprise South is expected to have a full production capacity of 31.5k tpa, bringing the company's total production capacity to over 50k tpa[68] Commercial Traction - NOVONIX has a 4-year commitment totaling 10,000 tonnes with Panasonic and a 5-year commitment for a minimum of 32,000 tonnes with PowerCo starting in 2027[72] - The company is currently sampling to 15 current and potential customers[72] - NOVONIX delivered its first mass production, commercial-grade sample of synthetic graphite for industrial applications[83]

Argentine Economy - Real Gross Domestic Product is projected to increase by 3.6% in 2025 and 3.9% in 2026[5] - The Non-Financial Public Sector's Primary Fiscal Balance is projected to be 0.3% of GDP in both 2025 and 2026[14] - The Argentine Central Bank financing is projected to be 0.6% of GDP in 2025[16] - The current account is projected to be 0.3% of GDP in 2025[25] - Exports are projected to reach $81.5 billion in 2025 and $82.9 billion in 2026[26] Argentine Financial System - Financial Depth: Deposits are 18% of GDP and Loans are 10% of GDP in Argentina[44] - Private Sector Deposits increased 135.2% YoY and Private Sector Credit increased 135% YoY as of November 2025[49, 51] - As of August 31, 2025, Private Sector Banks hold 30.8% of the market share of private-sector deposits[62] - As of September 2025, the banking system's ROE is -0.1% and ROA is 0.0%[66, 67] Grupo Financiero Galicia (GFG) - GFG's ROE for 3Q25 was (4.7)% and ROA was (0.8)%[83] - Banco Galicia's ROE for 3Q25 was (7.3)% and ROA was (1.3)%[92] - Naranja X's ROE for 3Q25 was (2.5)% and ROA was (0.4)%[159]

FOURTH QUARTER FY2025 EARNINGS NOVEMBER 26, 2025 SAFE HARBOR The information provided in this presentation may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "aims", "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions ...

4Q 2025 Earnings Call 26 November 2025 Forward-Looking Statements This earnings call, this presentational and accompanying materials may include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "forecast," "guidance," "project," "target," "outlook," "prospects," "expect," "estimate," "will," "goal," "plan," "anticipate," "intend," "predict," "believe," "likely," " ...

Q3 2025 EARNINGS PRESENTATION 1 MV EFROSSINI EEDI-PHASE 3 – IMO NOx TIER III KAMSARMAX DELIVERED APRIL 2025 This presentation contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and in Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, the Company's growth strategy and measures to implement such strategy, including expected vessel acquisitions and entering into further time charters. Words such as "expects," "intend ...

BBVA Argentina November 2025 3Q25 Earnings Conference Call BBVA Argentina Corporate Presentation p. 1 3Q25 Profitability Indicators Net Income (AR$ billion, INFLATION ADJUSTED) -40% -46% ROA ROE BBVA Argentina Corporate Presentation p. 2 3Q25 Main Highlights – Ar$ Real Terms 3Q25 Net Income NET INTEREST INCOME OPERATING EXPENSES EFFICIENCY RATIO* (%) 57.6% in 3Q25 210.0 bn LOAN LOSS ALLOWANCES 1 3 2 585.5 bn FINANCIAL MARGIN 79.8 bn 494.6 bn -25.3% QoQ -33.6% YoY -6.6% QoQ -3.5% YoY +37.1% QoQ +286.3% YoY - ...

Business Performance - Loan book grew by 8% QoQ, outperforming the industry growth of 7.6%[8] - Total deposits increased by 15% QoQ and 40% YoY[8] - US$ deposits reached record levels, up 31% QoQ and 56% YoY[8] - Net fee income increased by 7% QoQ and 9% YTD[8] Profitability and Asset Quality - The company experienced a net loss of 50 billion in 3Q25 due to increased Cost of Risk (COR)[8] - Net Interest Margin (NIM) declined to 11%[8] - NPL ratio increased to 3.9%[8] - Net COR was 6.4% in 3Q25 and 5.2% YTD[8] Strategic Initiatives and Capital - CET1 ratio stood at 13.2% as of September 2025, increasing to 14.5% by October 2025[8, 18] - The company continued to evolve its SuperApp[8] - Cost reduction of 2% QoQ and 12% YTD was achieved[8] Macroeconomic Context - The Central Bank Market Expectations Survey as of October 2025 projected inflation of 30%, an Fx eop at 1,532, and GDP growth of 3.9% in 2025[15, 19]